Thursday, November 19

    IBN

    Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (“CDMO”) alongside an immunotherapy development platform, announced securities purchase and warrant inducement agreements with an existing institutional investor expected to generate approximately $4 million in aggregate